Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tunc Iyriboz

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanomaFederica Catalanotti, David B Solit, Melissa P Pulitzer, et al.
Clinical Lung Cancer|February 23, 2016
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and OutcomesJarushka Naidoo, Maria L Santos-Zabala, Tunc Iyriboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 TherapyJarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanomaFederica Catalanotti, David B Solit, Melissa P Pulitzer, et al.
Clinical Lung Cancer|February 23, 2016
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and OutcomesJarushka Naidoo, Maria L Santos-Zabala, Tunc Iyriboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 TherapyJarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Pageof 1